Split History
BOLT split history picture
Bolt Biotherapeutics (BOLT) has 1 split in our BOLT split history database. The split for BOLT took place on January 31, 2008. This was a 3 for 2 split, meaning for each 2 shares of BOLT owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split.

When a company such as Bolt Biotherapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the BOLT split history from start to finish, an original position size of 1000 shares would have turned into 1500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bolt Biotherapeutics shares, starting with a $10,000 purchase of BOLT, presented on a split-history-adjusted basis factoring in the complete BOLT split history. BOLT split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/05/2021
End date: 06/28/2022
Start price/share: $32.15
End price/share: $1.86
Dividends collected/share: $0.00
Total return: -94.21%
Average Annual Total Return: -87.15%
Starting investment: $10,000.00
Ending investment: $578.40
Years: 1.39
Bolt Biotherapeutics is involved in immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Co.'s proprietary Boltbody™ ISAC (immune-stimulating antibody conjugate) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including those with HER2-low tumors. According to our BOLT split history records, Bolt Biotherapeutics has had 1 split.
Date Ratio
01/31/20083 for 2
BOLT is categorized under the Energy sector; below are some other companies in the same sector that also have a history of stock splits:

BP Split History
BPL Split History
BRN Split History
BRY Split History
BT Split History
BWP Split History
BXE Split History
CAK Split History
CAM Split History
CEI Split History

Email EnvelopeFree BOLT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Borqs Technologies, Inc. (BRQS)
Staffing 360 Solutions, Inc. (STAF)
South Star Battery Metals Corp. (STS.CA)
Calithera Biosciences, Inc. (CALA)
TDH Holdings, Inc. (PETZ)
Fortinet (FTNT)
AIkido Pharma, Inc. (AIKI)
Histogen Inc. (HSTO)
Farmmi, Inc. (FAMI)
CASI Pharmaceuticals, Inc. (CASI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

BOLT Insider Buying

BOLT Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.